Skip to main content Skip to footer
HomeHome
 
  • Startseite
  • Patentrecherche

    Patentwissen

    Unsere Patentdatenbanken und Recherchetools

    Zur Übersicht 

    • Übersicht
    • Technische Information
      • Übersicht
      • Espacenet - Patentsuche
      • Europäischer Publikationsserver
      • EP-Volltextrecherche
    • Rechtliche Information
      • Übersicht
      • Europäisches Patentregister
      • Europäisches Patentblatt
      • European Case Law Identifier Sitemap
      • Einwendungen Dritter
    • Geschäftsinformationen
      • Übersicht
      • PATSTAT
      • IPscore
      • Technologieanalyseberichte
    • Daten
      • Übersicht
      • Technology Intelligence Platform
      • Linked open EP data
      • Massendatensätze
      • Web-Dienste
      • Datenbestände, Codes und Statistiken
    • Technologieplattformen
      • Übersicht
      • Kunststoffe im Wandel
      • Innovationen im Wassersektor
      • Innovationen im Weltraumsektor
      • Technologien zur Bekämpfung von Krebs
      • Technologien zur Brandbekämpfung
      • Saubere Energietechnologien
      • Kampf gegen Corona
    • Nützliche Informationsquellen
      • Übersicht
      • Zum ersten Mal hier? Was ist Patentinformation?
      • Patentinformation aus Asien
      • Patentinformationszentren (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Wirtschaft und Statistik
      • Patentinformationen rund um den einheitlichen Patentschutz
    Bild
    Plastics in Transition

    Technologieanalysebericht zur Plastikabfallwirtschaft

  • Anmelden eines Patents

    Anmelden eines Patents

    Praktische Informationen über Anmelde- und Erteilungsverfahren.

    Zur Übersicht 

    • Übersicht
    • Europäischer Weg
      • Übersicht
      • Leitfaden zum europäischen Patent
      • Einsprüche
      • Mündliche Verhandlung
      • Beschwerden
      • Einheitspatent & Einheitliches Patentgericht
      • Nationale Validierung
      • Antrag auf Erstreckung/Validierung
    • Internationaler Weg (PCT)
      • Übersicht
      • Euro-PCT-Leitfaden: PCT-Verfahren im EPA
      • Beschlüsse und Mitteilungen des EPA
      • PCT-Bestimmungen und Informationsquellen
      • Erstreckungs-/Validierungsantrag
      • Programm für verstärkte Partnerschaft
      • Beschleunigung Ihrer PCT-Anmeldung
      • Patent Prosecution Highway (PPH)
      • Schulungen und Veranstaltungen
    • Nationale Anmeldungen
    • Zugelassenen Vertreter suchen
    • MyEPO Services
      • Übersicht
      • Unsere Dienste verstehen
      • Zugriff erhalten
      • Bei uns einreichen
      • Akten interaktiv bearbeiten
      • Verfügbarkeit der Online-Dienste
    • Formblätter
      • Übersicht
      • Prüfungsantrag
    • Gebühren
      • Übersicht
      • Europäische Gebühren (EPÜ)
      • Internationale Gebühren (PCT)
      • Einheitspatentgebühren (UP)
      • Gebührenzahlung und Rückerstattung
      • Warnung

    UP

    Erfahren Sie, wie das Einheitspatent Ihre IP-Strategie verbessern kann

  • Recht & Praxis

    Recht & Praxis

    Europäisches Patentrecht, Amtsblatt und andere Rechtstexte

    Zur Übersicht 

    • Übersicht
    • Rechtstexte
      • Übersicht
      • Europäisches Patentübereinkommen
      • Amtsblatt
      • Richtlinien
      • Erstreckungs-/ Validierungssyste
      • Londoner Übereinkommen
      • Nationales Recht zum EPÜ
      • Système du brevet unitaire
      • Nationale Maßnahmen zum Einheitspatent
    • Gerichtspraxis
      • Übersicht
      • Symposium europäischer Patentrichter
    • Nutzerbefragungen
      • Übersicht
      • Laufende Befragungen
      • Abgeschlossene Befragungen
    • Harmonisierung des materiellen Patentrechts
      • Übersicht
      • The Tegernsee process
      • Gruppe B+
    • Konvergenz der Verfahren
    • Optionen für zugelassene Vertreter
    Bild
    Law and practice scales 720x237

    Informieren Sie sich über die wichtigsten Aspekte ausgewählter BK-Entscheidungen in unseren monatlichen „Abstracts of decisions“

  • Neues & Veranstaltungen

    Neues & Veranstaltungen

    Aktuelle Neuigkeiten, Podcasts und Veranstaltungen.

    Zur Übersicht 

     

    • Übersicht
    • News
    • Veranstaltungen
    • Europäischer Erfinderpreis
      • Übersicht
      • Die bedeutung von morgen
      • Über den Preis
      • Kategorien und Preise
      • Lernen Sie die Finalisten kennen
      • Nominierungen
      • European Inventor Network
      • Preisverleihung 2024
    • Young Inventor Prize
      • Übersicht
      • Über den Preis
      • Nominierungen
      • Die jury
      • Die Welt, neu gedacht
    • Pressezentrum
      • Übersicht
      • Patent Index und Statistiken
      • Pressezentrum durchsuchen
      • Hintergrundinformation
      • Copyright
      • Pressekontakt
      • Rückruf Formular
      • Presseinfos per Mail
    • Innovation und Patente im Blickpunkt
      • Übersicht
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Forschungseinrichtungen
      • Women inventors
      • Lifestyle
      • Raumfahrt und Satelliten
      • Zukunft der Medizin
      • Werkstoffkunde
      • Mobile Kommunikation: Das große Geschäft mit kleinen Geräten
      • Biotechnologiepatente
      • Patentklassifikation
      • Digitale Technologien
      • Die Zukunft der Fertigung
      • Books by EPO experts
    • Podcast "Talk innovation"

    Podcast

    Von der Idee zur Erfindung: unser Podcast informiert Sie topaktuell in Sachen Technik und IP

  • Lernen

    Lernen

    Europäische Patentakademie – unser Kursportal für Ihre Fortbildung

    Zur Übersicht 

    • Übersicht
    • Schulungsaktivitäten und Lernpfade
      • Übersicht
      • Schulungsaktivitäten
      • Lernpfade
    • EEP und EPVZ
      • Übersicht
      • Europäische Eignungsprüfung – EEP
      • Europäisches Patentverwaltungszertifikat – EPVZ
      • Projekt zur Unterstützung von EEP-Bewerbern
    • Lernmaterial nach Interesse
      • Übersicht
      • Patenterteilung
      • Technologietransfer und -verbreitung
      • Durchsetzung
    • Lernmaterial nach Profil
      • Übersicht
      • Geschäftswelt und IP
      • EEP und EPVZ Bewerber
      • Justiz
      • Nationale Ämter und IP-Behörden
      • Patentanwaltskanzleien
      • Lehre und Forschung
    Bild
    Patent Academy catalogue

    Werfen Sie einen Blick auf das umfangreiche Lernangebot im Schulungskatalog der Europäischen Patentakademie

  • Über uns

    Über uns

    Erfahren Sie mehr über Tätigkeit, Werte, Geschichte und Vision des EPA

    Zur Übersicht 

    • Übersicht
    • Das EPA auf einen Blick
    • 50 Jahre Europäisches Patentübereinkommen
      • Übersicht
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kinderwettbewerb für kollektive Kunst
    • Rechtsgrundlagen und Mitgliedstaaten
      • Übersicht
      • Rechtsgrundlagen
      • Mitgliedstaaten der Europäischen Patentorganisation
      • Erstreckungsstaaten
      • Validierungsstaaten
    • Verwaltungsrat und nachgeordnete Organe
      • Übersicht
      • Kommuniqués
      • Kalender
      • Dokumente und Veröffentlichungen
      • Der Verwaltungsrat der Europäischen Patentorganisation
    • Unsere Grundsätze und Strategie
      • Übersicht
      • Auftrag, Vision und Werte
      • Strategischer Plan 2028
      • Auf dem Weg zu einer neuen Normalität
    • Führung und Management
      • Übersicht
      • Präsident António Campinos
      • Managementberatungsausschuss
    • Sustainability at the EPO
      • Übersicht
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Dienste & Aktivitäten
      • Übersicht
      • Unsere Dienste & Struktur
      • Qualität
      • Nutzerkonsultation
      • Europäische und internationale Zusammenarbeit
      • Europäische Patentakademie
      • Chefökonom
      • Ombudsstelle
      • Meldung von Fehlverhalten
    • Beobachtungsstelle für Patente und Technologie
      • Übersicht
      • Akteure im Innovationsbereich
      • Politisches Umfeld und Finanzierung
      • Tools
      • Über die Beobachtungsstelle
    • Beschaffung
      • Übersicht
      • Beschaffungsprognose
      • Das EPA als Geschäftspartner
      • Beschaffungsverfahren
      • Nachhaltiger Beschaffungsstandard
      • Registrierung zum eTendering und elektronische Signaturen
      • Beschaffungsportal
      • Rechnungsstellung
      • Allgemeine Bedingungen
      • Archivierte Ausschreibungen
    • Transparenzportal
      • Übersicht
      • Allgemein
      • Humankapital
      • Umweltkapital
      • Organisationskapital
      • Sozial- und Beziehungskapital
      • Wirtschaftskapital
      • Governance
    • Statistics and trends
      • Übersicht
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • Die Geschichte des EPA
      • Übersicht
      • 1970er-Jahre
      • 1980er-Jahre
      • 1990er-Jahre
      • 2000er-Jahre
      • 2010er-Jahre
      • 2020er Jahre
    • Die EPA Kunstsammlung
      • Übersicht
      • Die Sammlung
      • Let's talk about art
      • Künstler
      • Mediathek
      • What's on
      • Publikationen
      • Kontakt
      • Kulturraum A&T 5-10
      • "Lange Nacht"
    Bild
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Verfolgen Sie die neuesten Technologietrends mit unserem Patentindex

 
Website
cancel
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • Sind Patente Neuland für Sie?
    • Go back
    • Übersicht
    • Was ist Ihre zündende Idee?
    • Sind Sie bereit?
    • Darum geht es
    • Der Weg zum Patent
    • Patente für Ihr Unternehmen?
    • Ist es patentierbar?
    • Ist Ihnen jemand zuvorgekommen?
    • Warum ein Patent?
    • Patentquiz
    • Video zum Einheitspatent
  • Patentrecherche
    • Go back
    • Übersicht
    • Technische Information
      • Go back
      • Übersicht
      • Espacenet - Patentsuche
        • Go back
        • Übersicht
        • Datenbanken der nationalen Ämter
        • Global Patent Index (GPI)
        • Versionshinweise
      • Europäischer Publikationsserver
        • Go back
        • Übersicht
        • Versionshinweise
        • Konkordanzliste für Euro-PCT-Anmeldungen
        • EP-Normdatei
        • Hilfe
      • EP-Volltextrecherche
    • Rechtliche Information
      • Go back
      • Übersicht
      • Europäisches Patentregister
        • Go back
        • Übersicht
        • Versionshinweise: Archiv
        • Dokumentation zu Register
          • Go back
          • Übersicht
          • Datenverfügbarkeit für Deep Links
          • Vereinigtes Register
          • Ereignisse im Register
      • Europäisches Patentblatt
        • Go back
        • Übersicht
        • Patentblatt herunterladen
        • Recherche im Europäischen Patentblatt
        • Hilfe
      • European Case Law Identifier Sitemap
      • Einwendungen Dritter
    • Geschäftsinformationen
      • Go back
      • Übersicht
      • PATSTAT
      • IPscore
        • Go back
        • Versionshinweise
      • Technologieanalyseberichte
    • Daten
      • Go back
      • Übersicht
      • Technology Intelligence Platform
      • Linked open EP data
      • Massendatensätze
        • Go back
        • Übersicht
        • Manuals
        • Sequenzprotokolle
        • Nationale Volltextdaten
        • Daten des Europäischen Patentregisters
        • Weltweite bibliografische Daten des EPA (DOCDB)
        • EP-Volltextdaten
        • Weltweite Rechtsereignisdaten des EPA (INPADOC)
        • Bibliografische Daten von EP-Dokumenten (EBD)
        • Entscheidungen der Beschwerdekammern des EPA
      • Web-Dienste
        • Go back
        • Übersicht
        • Open Patent Services (OPS)
        • Europäischer Publikationsserver (Web-Dienst)
      • Datenbestände, Codes und Statistiken
        • Go back
        • Wöchentliche Aktualisierungen
        • Regelmäßige Aktualisierungen
    • Technologieplattformen
      • Go back
      • Kunststoffe im Wandel
        • Go back
        • Overview
        • Verwertung von Plastikabfällen
        • Recycling von Plastikabfällen
        • Alternative Kunststoffe
      • Übersicht
      • Innovative Wassertechnologien
        • Go back
        • Overview
        • Sauberes Wasser
        • Schutz vor Wasser
      • Innovationen im Weltraumsektor
        • Go back
        • Übersicht
        • Kosmonautik
        • Weltraumbeobachtung
      • Technologien zur Bekämpfung von Krebs
        • Go back
        • Übersicht
        • Prävention und Früherkennung
        • Diagnostik
        • Therapien
        • Wohlergehen und Nachsorge
      • Technologien zur Brandbekämpfung
        • Go back
        • Übersicht
        • Branderkennung und -verhütung
        • Feuerlöschen
        • Schutzausrüstung
        • Technologien für die Sanierung nach Bränden
      • Saubere Energietechnologien
        • Go back
        • Übersicht
        • Erneuerbare Energien
        • CO2-intensive Industrien
        • Energiespeicherung und andere Enabling-Technologien
      • Kampf gegen Corona
        • Go back
        • Übersicht
        • Impfstoffe und Therapeutika
          • Go back
          • Übersicht
          • Impfstoffe
          • Übersicht über Therapieansätze für COVID-19
          • Kandidaten für antivirale Therapeutika
          • Nukleinsäuren zur Behandlung von Coronavirus-Infektionen
        • Diagnose und Analyse
          • Go back
          • Übersicht
          • Protein-und Nukleinsäure-Nachweis
          • Analyseprotokolle
        • Informatik
          • Go back
          • Übersicht
          • Bioinformatik
          • Medizinische Informatik
        • Technologien für die neue Normalität
          • Go back
          • Übersicht
          • Geräte, Materialien und Ausrüstung
          • Verfahren, Maßnahmen und Aktivitäten
          • Digitale Technologien
        • Erfinderinnen und Erfinder gegen das Coronavirus
    • Nützliche Informationsquellen
      • Go back
      • Übersicht
      • Zum ersten Mal hier? Was ist Patentinformation?
        • Go back
        • Übersicht
        • Grundlegende Definitionen
        • Patentklassifikation
          • Go back
          • Übersicht
          • Gemeinsame Patentklassifikation
        • Patentfamilien
          • Go back
          • Übersicht
          • Einfache DOCDB Patentfamilie
          • Erweiterte INPADOC Patentfamilie
        • Daten zu Rechtsstandsereignissen
          • Go back
          • Übersicht
          • INPADOC-Klassifikationssystem
      • Patentinformation aus Asien
        • Go back
        • Übersicht
        • China (CN)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinesisch-Taipei (TW)
          • Go back
          • Übersicht
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Indien (IN)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Übersicht
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russische Föderation (RU)
          • Go back
          • Übersicht
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patentinformationszentren (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Wirtschaft und Statistik
      • Patentinformationen rund um den einheitlichen Patentschutz
  • Anmelden eines Patents
    • Go back
    • Übersicht
    • Europäischer Weg
      • Go back
      • Übersicht
      • Leitfaden zum europäischen Patent
      • Einsprüche
      • Mündliche Verhandlung
        • Go back
        • Kalender der mündlichen Verhandlungen
          • Go back
          • Kalender der mündlichen Verhandlungen
          • Technische Richtlinien
          • Zugang für die Öffentlichkeit zum Beschwerdeverfahren
          • Zugang für die Öffentlichkeit zum Einspruchsverfahren
      • Beschwerden
      • Einheitspatent & Einheitliches Patentgericht
        • Go back
        • Einheitspatent
          • Go back
          • Übersicht
          • Rechtlicher Rahmen
          • Wesentliche Merkmale
          • Beantragung eines Einheitspatents
          • Kosten eines Einheitspatents
          • Übersetzungsregelungen und Kompensationssystem
          • Starttermin
          • Introductory brochures
        • Übersicht
        • Einheitliches Patentgericht
      • Nationale Validierung
      • Erstreckungs- /Validierungsantrag
    • Internationaler Weg
      • Go back
      • Übersicht
      • Euro-PCT-Leitfaden
      • Eintritt in die europäische Phase
      • Beschlüsse und Mitteilungen
      • PCT-Bestimmungen und Informationsquellen
      • Erstreckungs-/Validierungsantrag
      • Programm für verstärkte Partnerschaft
      • Beschleunigung Ihrer PCT-Anmeldung
      • Patent Prosecution Highway (PPH)
        • Go back
        • Programm "Patent Prosecution Highway" (PPH) - Übersicht
      • PCT: Schulungen und Veranstaltungen
    • Nationaler Weg
    • MyEPO Services
      • Go back
      • Übersicht
      • Unsere Dienste verstehen
        • Go back
        • Übersicht
        • Exchange data with us using an API
          • Go back
          • Versionshinweise
      • Zugriff erhalten
        • Go back
        • Übersicht
        • Versionshinweise
      • Bei uns einreichen
        • Go back
        • Bei uns einreichen
        • Wenn unsere Dienste für die Online-Einreichung ausfallen
        • Versionshinweise
      • Akten interaktiv bearbeiten
        • Go back
        • Versionshinweise
      • Verfügbarkeit der Online-Dienste
    • Gebühren
      • Go back
      • Übersicht
      • Europäische Gebühren (EPÜ)
        • Go back
        • Übersicht
        • Beschlüsse und Mitteilungen
      • Internationale Gebühren (PCT)
        • Go back
        • Ermäßigung der Gebühren
        • Gebühren für internationale Anmeldungen
        • Beschlüsse und Mitteilungen
        • Übersicht
      • Einheitspatentgebühren (UP)
        • Go back
        • Übersicht
        • Beschlüsse und Mitteilungen
      • Gebührenzahlung und Rückerstattung
        • Go back
        • Übersicht
        • Zahlungsarten
        • Erste Schritte
        • FAQs und sonstige Anleitungen
        • Technische Informationen für Sammelzahlungen
        • Beschlüsse und Mitteilungen
        • Versionshinweise
      • Warnung
    • Formblätter
      • Go back
      • Prüfungsantrag
      • Übersicht
    • Zugelassenen Vertreter suchen
  • Recht & Praxis
    • Go back
    • Übersicht
    • Rechtstexte
      • Go back
      • Übersicht
      • Europäisches Patentübereinkommen
        • Go back
        • Übersicht
        • Archiv
          • Go back
          • Übersicht
          • Dokumentation zur EPÜ-Revision 2000
            • Go back
            • Übersicht
            • Diplomatische Konferenz für die Revision des EPÜ
            • "Travaux préparatoires" (Vorarbeiten)
            • Neufassung
            • Übergangsbestimmungen
            • Ausführungsordnung zum EPÜ 2000
            • Gebührenordnung
            • Ratifikationen und Beitritte
          • Travaux Préparatoires EPÜ 1973
      • Amtsblatt
      • Richtlinien
        • Go back
        • Übersicht
        • EPÜ Richtlinien
        • PCT-EPA Richtlinien
        • Richtlinien für das Einheitspatent
        • Überarbeitung der Richtlinien
        • Ergebnisse der Konsultation
        • Zusammenfassung der Nutzerbeiträge
        • Archiv
      • Erstreckungs-/Validierungssystem
      • Londoner Übereinkommen
      • Nationales Recht zum EPÜ
        • Go back
        • Übersicht
        • Archiv
      • Einheitspatentsystem
        • Go back
        • Travaux préparatoires to UP and UPC
      • Nationale Maßnahmen zum Einheitspatent
    • Gerichtspraxis
      • Go back
      • Übersicht
      • Symposium europäischer Patentrichter
    • Nutzerbefragungen
      • Go back
      • Übersicht
      • Laufende Befragungen
      • Abgeschlossene Befragungen
    • Harmonisierung des materiellen Patentrechts
      • Go back
      • Übersicht
      • The Tegernsee process
      • Gruppe B+
    • Konvergenz der Verfahren
    • Optionen für zugelassene Vertreter
  • Neues & Veranstaltungen
    • Go back
    • Übersicht
    • News
    • Veranstaltungen
    • Europäischer Erfinderpreis
      • Go back
      • The meaning of tomorrow
      • Übersicht
      • Über den Preis
      • Kategorien und Preise
      • Lernen Sie die Erfinder kennen
      • Nominierungen
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • Preisverleihung 2024
    • Young Inventors Prize
      • Go back
      • Übersicht
      • Über den Preis
      • Nominierungen
      • Die Jury
      • Die Welt, neu gedacht
      • Preisverleihung 2025
    • Pressezentrum
      • Go back
      • Übersicht
      • Patent Index und Statistiken
      • Pressezentrum durchsuchen
      • Hintergrundinformation
        • Go back
        • Übersicht
        • Europäisches Patentamt
        • Fragen und Antworten zu Patenten im Zusammenhang mit dem Coronavirus
        • Fragen und Antworten zu Pflanzenpatenten
      • Copyright
      • Pressekontakt
      • Rückruf Formular
      • Presseinfos per Mail
    • Im Blickpunkt
      • Go back
      • Übersicht
      • Wasserbezogene Technologien
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Übersicht
        • CodeFest 2024 zu generativer KI
        • Codefest 2023 zu grünen Kunststoffen
      • Green tech in focus
        • Go back
        • Übersicht
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Forschungseinrichtungen
      • Women inventors
      • Lifestyle
      • Raumfahrt und Satelliten
        • Go back
        • Weltraumtechnologie und Patente
        • Übersicht
      • Gesundheit
        • Go back
        • Übersicht
        • Medizintechnik und Krebs
        • Personalised medicine
      • Werkstoffkunde
        • Go back
        • Übersicht
        • Nanotechnologie
      • Mobile Kommunikation
      • Biotechnologie
        • Go back
        • Rot, weiß oder grün
        • Übersicht
        • Die Rolle des EPA
        • Was ist patentierbar?
        • Biotechnologische Erfindungen und ihre Erfinder
      • Patentklassifikation
        • Go back
        • Übersicht
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Übersicht
          • External partners
          • Updates on Y02 and Y04S
      • Digitale Technologien
        • Go back
        • Übersicht
        • Über IKT
        • Hardware und Software
        • Künstliche Intelligenz
        • Vierte Industrielle Revolution
      • Additive Fertigung
        • Go back
        • Übersicht
        • Die additive Fertigung
        • Innovation durch AM
      • Books by EPO experts
    • Podcast
  • Lernen
    • Go back
    • Übersicht
    • Schulungsaktivitäten und Lernpfade
      • Go back
      • Übersicht
      • Schulungsaktivitäten: Arten und Formate
      • Lernpfade
    • EEP und EPVZ
      • Go back
      • Übersicht
      • Europäische Eignungsprüfung – EEP
        • Go back
        • Übersicht
        • Compendium
          • Go back
          • Übersicht
          • Aufgabe F
          • Aufgabe A
          • Aufgabe B
          • Aufgabe C
          • Aufgabe D
          • Vorprüfung
        • Erfolgreiche Bewerber
        • Archiv
      • Europäisches Patentverwaltungszertifikat – EPVZ
      • Projekt zur Unterstützung von EEP-Bewerbern
    • Angebot für bestimmte Interessengebiete
      • Go back
      • Übersicht
      • Patenterteilung
      • Technologietransfer und -verbreitung
      • Patentdurchsetzung und Streitregelung
    • Angebot für bestimmte Zielgruppen
      • Go back
      • Übersicht
      • Geschäftswelt und IP
        • Go back
        • Übersicht
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Fallstudien zum Technologietransfer
          • Fallstudien zu wachstumsstarken Technologien
        • Inventor's handbook
          • Go back
          • Übersicht
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Übersicht
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Übersicht
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EEP und EPVZ Bewerber
        • Go back
        • Übersicht
        • Denkaufgaben zu Aufgabe F
        • Tägliche Fragen zur Aufgabe D
        • Europäische Eignungsprüfung - Leitfaden zur Vorbereitung
        • EPVZ
      • Richter, Anwälte und Staatsanwälte
        • Go back
        • Übersicht
        • Compulsory licensing in Europe
        • Die Zuständigkeit europäischer Gerichte bei Patentstreitigkeiten
      • Nationale Ämter und IP-Behörden
        • Go back
        • Übersicht
        • Lernpfad für Patentprüfer der nationalen Ämter
        • Lernpfad für Formalsachbearbeiter und Paralegals
      • Patentanwaltskanzleien
      • Hochschulen, Forschungseinrichtungen und Technologietransferstellen
        • Go back
        • Übersicht
        • Modularer IP-Ausbildungsrahmen (MIPEF)
        • Programm "Pan-European-Seal für junge Fachkräfte"
          • Go back
          • Übersicht
          • Für Studierende
          • Für Hochschulen
            • Go back
            • Übersicht
            • IP-Schulungsressourcen
            • Hochschulmitgliedschaften
          • Unsere jungen Fachkräfte
          • Beruflicher Entwicklungsplan
        • Akademisches Forschungsprogramm (ARP)
          • Go back
          • Übersicht
          • Abgeschlossene Forschungsprojekte
          • Laufende Forschungsprojekte
        • IP Teaching Kit
          • Go back
          • Übersicht
          • Download modules
        • Handbuch für die Gestaltung von IP-Kursen
        • PATLIB Wissenstransfer nach Afrika
          • Go back
          • Die PATLIB-Initiative "Wissenstransfer nach Afrika" (KT2A)
          • KT2A-Kernaktivitäten
          • Erfolgsgeschichte einer KT2A-Partnerschaft: PATLIB Birmingham und Malawi University of Science and Technology
  • Über uns
    • Go back
    • Übersicht
    • Das EPA auf einen Blick
    • 50 Jahre EPÜ
      • Go back
      • Official celebrations
      • Übersicht
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kinderwettbewerb für kollektive Kunst
    • Rechtsgrundlagen und Mitgliedstaaten
      • Go back
      • Übersicht
      • Rechtsgrundlagen
      • Mitgliedstaaten
        • Go back
        • Übersicht
        • Mitgliedstaaten sortiert nach Beitrittsdatum
      • Erstreckungsstaaten
      • Validierungsstaaten
    • Verwaltungsrat und nachgeordnete Organe
      • Go back
      • Übersicht
      • Kommuniqués
        • Go back
        • 2024
        • Übersicht
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Kalender
      • Dokumente und Veröffentlichungen
        • Go back
        • Übersicht
        • Dokumente des Engeren Ausschusses
      • Verwaltungsrat
        • Go back
        • Übersicht
        • Zusammensetzung
        • Vertreter
        • Geschäftsordnung
        • Kollegium der Rechnungsprüfer
        • Sekretariat
        • Nachgeordnete Organe
    • Grundsätze
      • Go back
      • Übersicht
      • Auftrag, Vision und Werte
      • Strategieplan 2028
        • Go back
        • Treiber 1: Personal
        • Treiber 2: Technologien
        • Treiber 3: Qualitativ hochwertige Produkte und Dienstleistungen
        • Treiber 4: Partnerschaften
        • Treiber 5: Finanzielle Nachhaltigkeit
      • Auf dem Weg zu einer neuen Normalität
      • Datenschutzerklärung
    • Führung und Management
      • Go back
      • Übersicht
      • Über den Präsidenten
      • Managementberatungsausschuss
    • Nachhaltigkeit beim EPA
      • Go back
      • Overview
      • Umwelt
        • Go back
        • Overview
        • Inspirierende Erfindungen für die Umwelt
      • Soziales
        • Go back
        • Overview
        • Inspirierende soziale Erfindungen
      • Governance und finanzielle Nachhaltigkeit
    • Beschaffung
      • Go back
      • Übersicht
      • Beschaffungsprognose
      • Das EPA als Geschäftspartner
      • Beschaffungsverfahren
      • Veröffentlichungen des Dynamischen Beschaffungssystems
      • Nachhaltiger Beschaffungsstandard
      • Über eTendering
      • Rechnungsstellung
      • Beschaffungsportal
        • Go back
        • Übersicht
        • Elektronische Signatur von Verträgen
      • Allgemeine Bedingungen
      • Archivierte Ausschreibungen
    • Dienste & Aktivitäten
      • Go back
      • Übersicht
      • Unsere Dienste & Struktur
      • Qualität
        • Go back
        • Übersicht
        • Grundlagen
          • Go back
          • Übersicht
          • Europäisches Patentübereinkommen
          • Richtlinien für die Prüfung
          • Unsere Bediensteten
        • Qualität ermöglichen
          • Go back
          • Übersicht
          • Stand der Technik
          • Klassifikationssystem
          • Tools
          • Qualitätssicherung
        • Produkte & Dienstleistungen
          • Go back
          • Übersicht
          • Recherche
          • Prüfung
          • Einspruch
          • Fortlaufende Verbesserung
        • Qualität durch Netzwerke
          • Go back
          • Übersicht
          • Nutzerengagement
          • Zusammenarbeit
          • Befragung zur Nutzerzufriedenheit
          • Stakeholder-Qualitätssicherungspanels
        • Charta für Patentqualität
        • Qualitätsaktionsplan
        • Qualitäts-Dashboard
        • Statistik
          • Go back
          • Übersicht
          • Recherche
          • Prüfung
          • Einspruch
        • Integriertes Management beim EPA
      • Charta unserer Kundenbetreuung
      • Nutzerkonsultation
        • Go back
        • Übersicht
        • Ständiger Beratender Ausschuss beim EPA
          • Go back
          • Übersicht
          • Ziele
          • Der SACEPO und seine Arbeitsgruppen
          • Sitzungen
          • Bereich für Delegierte
        • Befragungen
          • Go back
          • Übersicht
          • Methodik
          • Recherche
          • Sachprüfung, abschließende Aktionen und Veröffentlichung
          • Einspruch
          • Formalprüfung
          • Kundenbetreuung
          • Einreichung
          • Key Account Management (KAM)
          • EPA-Website
          • Archiv
      • Europäische und internationale Zusammenarbeit
        • Go back
        • Übersicht
        • Zusammenarbeit mit den Mitgliedstaaten
          • Go back
          • Übersicht
        • Bilaterale Zusammenarbeit mit Nichtmitgliedstaaten
          • Go back
          • Übersicht
          • Validierungssystem
          • Programm für verstärkte Partnerschaft
        • Internationale Organisationen, Trilaterale und IP5
        • Zusammenarbeit mit internationalen Organisationen außerhalb des IP-Systems
      • Europäische Patentakademie
        • Go back
        • Übersicht
        • Partner
      • Chefökonom
        • Go back
        • Übersicht
        • Wirtschaftliche Studien
      • Ombudsstelle
      • Meldung von Fehlverhalten
    • Beobachtungsstelle für Patente und Technologie
      • Go back
      • Übersicht
      • Innovation gegen Krebs
      • Akteure im Innovationsbereich
        • Go back
        • Übersicht
        • Start-ups und KMU
      • Politisches Umfeld und Finanzierung
        • Go back
        • Übersicht
        • Programm zur Innovationsfinanzierung
          • Go back
          • Übersicht
          • Unsere Studien zur Innovationsfinanzierung
          • EPA-Initiativen für Patentanmelder/innen
          • Programm zur Innovationsfinanzierung
        • Patente und Normen
          • Go back
          • Übersicht
          • Publikationen
          • Patent standards explorer
      • Tools
        • Go back
        • Übersicht
        • Deep Tech Finder
      • Über die Beobachtungsstelle
        • Go back
        • Übersicht
        • Arbeitsplan
    • Transparency portal
      • Go back
      • Übersicht
      • Allgemein
        • Go back
        • Übersicht
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Übersicht
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Humankapital
      • Umweltkapital
      • Organisationskapital
      • Sozial- und Beziehungskapital
      • Wirtschaftskapital
      • Governance
    • Statistics and trends
      • Go back
      • Übersicht
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • Geschichte
      • Go back
      • Übersicht
      • 1970er-Jahre
      • 1980er-Jahre
      • 1990er-Jahre
      • 2000er-Jahre
      • 2010er-Jahre
      • 2020er Jahre
    • Kunstsammlung
      • Go back
      • Übersicht
      • Die Sammlung
      • Let's talk about art
      • Künstler
      • Mediathek
      • What's on
      • Publikationen
      • Kontakt
      • Kulturraum A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Frühere Ausstellungen
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Lange Nacht"
  • Beschwerdekammern
    • Go back
    • Übersicht
    • Entscheidungen der Beschwerdekammern
      • Go back
      • Neue Entscheidungen
      • Übersicht
      • Ausgewählte Entscheidungen
    • Mitteilungen der Beschwerdekammern
    • Verfahren
    • Mündliche Verhandlungen
    • Über die Beschwerdekammern
      • Go back
      • Übersicht
      • Präsident der Beschwerdekammern
      • Große Beschwerdekammer
        • Go back
        • Übersicht
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technische Beschwerdekammern
      • Juristische Beschwerdekammer
      • Beschwerdekammer in Disziplinarangelegenheiten
      • Präsidium
        • Go back
        • Übersicht
    • Verhaltenskodex
    • Geschäftsverteilungsplan
      • Go back
      • Übersicht
      • Technical boards of appeal by IPC in 2025
      • Archiv
    • Jährliche Liste der Verfahren
    • Mitteilungen
    • Jahresberichte
      • Go back
      • Übersicht
    • Veröffentlichungen
      • Go back
      • Abstracts of decisions
    • Rechtsprechung der Beschwerdekammern
      • Go back
      • Übersicht
      • Archiv
  • Service & Unterstützung
    • Go back
    • Übersicht
    • Aktualisierungen der Website
    • Verfügbarkeit der Online-Dienste
      • Go back
      • Übersicht
    • FAQ
      • Go back
      • Übersicht
    • Veröffentlichungen
    • Bestellung
      • Go back
      • Patentwissen – Produkte und Dienste
      • Übersicht
      • Allgemeine Geschäftsbedingungen
        • Go back
        • Übersicht
        • Patentinformationsprodukte
        • Massendatensätze
        • Open Patent Services (OPS)
        • Leitfaden zur fairen Nutzung
    • Verfahrensbezogene Mitteilungen
    • Nützliche Links
      • Go back
      • Übersicht
      • Patentämter der Mitgliedstaaten
      • Weitere Patentämter
      • Verzeichnisse von Patentvertretern
      • Patentdatenbanken, Register und Patentblätter
      • Haftungsausschluss
    • Aboverwaltung
      • Go back
      • Übersicht
      • Anmelden
      • Einstellungen verwalten
      • Abmelden
    • Veröffentlichungen
      • Go back
      • Übersicht
      • Möglichkeiten der Einreichung
      • Standorte
    • Offizielle Feiertage
    • Glossar
    • RSS-Feeds
Board of Appeals
Decisions

Recent decisions

Übersicht
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Startseite
  2. Node
  3. T 0067/05 (Tetanus vaccine/EVANS) 25-09-2007
Facebook X Linkedin Email

T 0067/05 (Tetanus vaccine/EVANS) 25-09-2007

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2007:T006705.20070925
Datum der Entscheidung:
25 September 2007
Aktenzeichen
T 0067/05
Antrag auf Überprüfung von
-
Anmeldenummer
93910244.8
IPC-Klasse
A61K 39/08
Verfahrenssprache
EN
Verteilung
NO DISTRIBUTION (D)

Download und weitere Informationen:

Entscheidung in EN 131.05 KB
Alle Dokumente zum Beschwerdeverfahren finden Sie im Europäisches Patentregister
Bibliografische Daten verfügbar in:
EN
Fassungen
Nicht veröffentlicht
Bezeichnung der Anmeldung

Tetanus vaccine production

Name des Anmelders
Evans Vaccines Limited
Name des Einsprechenden
Sanofi Pasteur Limited
Kammer
3.3.04
Leitsatz
-
Relevante Rechtsnormen
European Patent Convention Art 54(1) 1973
European Patent Convention Art 54(2) 1973
European Patent Convention Art 56 1973
European Patent Convention Art 83 1973
European Patent Convention Art 84 1973
European Patent Convention Art 123(2) 1973
European Patent Convention Art 123(3) 1973
European Patent Convention R 26(2)(c) 1973
European Patent Convention R 57a 1973
European Patent Convention R 64(a) 1973
European Patent Convention R 65(2) 1973
Schlagwörter

Admissibility of appeal (yes)

Main request - inventive step (no)

Admission of auxiliary request into the proceedings (yes)

Auxiliary request: added subject-matter and extension of scope of protection (no); novelty, inventive step and sufficiency of disclosure (yes)

Orientierungssatz
-
Angeführte Entscheidungen
T 0939/92
T 0149/93
T 0097/98
T 1329/04
T 1599/06
Anführungen in anderen Entscheidungen
-

Summary of Facts and Submissions

I. European patent 0 652 771 is based on European patent application 93910244.8 filed as international application PCT/GB93/01037 and has the title "Tetanus vaccine production". It was granted with nine claims.

Claims 1 and 5 as granted read:

"1. A process for the preparation of tetanus toxoid, which process comprises incubating purified tetanus toxin having a specific activity of 2000 Lf/mg PN (Limes flocculationis/mg protein nitrogen) or more and an Lf content of 250 Lf/ml or more with 0.2 to 1% (V/V) formaldehyde in the presence of 0.005 to 0.25M lysine for from 24 to 32 days at a pH of from 6.0 to 8.0 and a temperature of from 30 to 45ºC.

5. A process according to any one of the preceding claims, wherein the purified toxin is preincubated with the formaldehyde in the absence of the lysine for from 20 to 40 minutes at from 35 to 40ºC."

II. An opposition was filed by Aventis Pasteur Limited. The opposition was based on Article 100(a) EPC on the ground of lack of inventive step (Article 56 EPC) and on Article 100(b) EPC.

III. The opposition division decided to reject the opposition pursuant to Article 102(2) EPC. As regards inventive step, it considered document D2 and the formaldehyde-based detoxification process disclosed therein as the closest prior art and identified the objective technical problem as how to provide an improved process for the preparation of tetanus toxoid suitable for vaccine formulation, which does not exhibit adverse toxic reversion reactions, starting from a purified toxin. The opposition division held that even if the skilled person, despite being aware of the differences, had expected the reversion problem known for diphtheria also to occur in the context of tetanus detoxification, he/she would not have been in a one way street situation in overcoming the problem, since there had been conflicting views as to stabilising additives in documents D2, D6 and D9. The addition of lysine as a solution to the problem for the reason that it had been chosen for the detoxification of diphtheria toxin could therefore only be considered obvious with hindsight knowledge from the teaching of the contested patent.

With regard to the requirements of Article 83 EPC the opposition division essentially found that the opponent had not discharged its burden of proof for demonstrating that an undue burden was put on the skilled person wanting to rework the invention.

In the decision it was moreover held that document D14 filed by the opponent a few days before the oral proceedings was not admitted because it was not considered prima facie relevant.

IV. An appeal was lodged against this decision on 13 January 2005 "on behalf of the opponent, Aventis Pasteur Limited". With the statement of the grounds of appeal, documents D11 to D13 and documents D15 to D22 were filed, as well as a complete copy of document D14.

The patentee (respondent) replied to the statement of grounds of appeal and filed documents D25 and D26.

Further written submissions were filed by both parties.

V. Oral proceedings were held on 25 September 2007.

VI. At the oral proceedings the board informed the parties about a letter submitted on behalf of the appellant in appeal case T 1193/03 on 24 January 2006. The letter contained information about a change of the appellant's name into "Sanofi Pasteur Limited" and included supporting documents. The appellant requested that the same change of name be recorded in the present case and that the erroneous statement of the name in the notice of appeal be corrected in accordance with Rule 65(2) EPC.

VII. As a reaction to the conclusions of the board at the oral proceedings with respect to the main request, the respondent did not maintain its previous auxiliary request filed by letter of 5 December 2005, but submitted two new auxiliary requests ("Auxiliary Request 2" and "Auxiliary Request 3").

Claim 1 of auxiliary request 2 read:

"1. A process for the preparation of tetanus toxoid, which process comprises incubating purified tetanus toxin having a specific activity of 2000 Lf/mg PN (Limes flocculationis/mg protein nitrogen) or more and an Lf content of 250 Lf/ml or more with 0.2 to 1% (V/V) formaldehyde in the presence of 0.005 to 0.25M lysine for from 24 to 32 days at a pH of from 6.0 to 8.0 and a temperature of from 30 to 45ºC, wherein the purified toxin is preincubated with the formaldehyde in the absence of the lysine for from 20 to 40 minutes at from 35 to 40ºC."

The request contained seven dependent claims.

VIII. The appellant requested that the decision under appeal be set aside and that the patent be revoked.

The respondent requested that the appeal be dismissed or, in the alternative, that the decision under appeal be set aside and the patent be maintained in amended form on the basis of auxiliary requests 2 or 3.

IX. At the end of the oral proceedings the board announced the decision.

X. The following documents are referred to hereinafter:

D2: Rappuoli, R., "New and improved vaccines against diphtheria and tetanus" (chapter 17); in: Woodrow, G.C. and Levine, M.M. (eds), "New generation vaccines", 1990, pages 251-268

D6: GB-A-969772

D9: US-A-4996299

D10: Pappenheimer, Jr., A.M., "Diphtheria"; in: Germanier, R. (ed), "Bacterial vaccines", 1984, pages 1 to 36

D14: World Health Organisation, WHO Technical Report Series 800, 1990, pages 87-179, "Requirements for diphtheria, tetanus, pertussis and combined vaccines"

D22: Linggood, F.V. et al., British Journal of Experimental Pathology, 1962, vol. XLIV, No. 2, pages 177-188

D23: Affidavit of Prof. C. Montecucco dated 21 March 2005

D25: Relyveld, E.H. and Ben-Efraim, S., Methods in Enzymology, vol. 93, 1983, pages 24-60, "Preparation of vaccines by the action of glutaraldehyde on toxins, bacteria, viruses, allergens, and cells"

XI. The appellant's arguments, as far as they are relevant for the present decision, may be summarised as follows:

Main request

Inventive step

Detoxification of pre-purified tetanus toxin was known, for example, from document D2 and also its detoxification with formaldehyde, being qualified in document D2 as the "conventional" detoxification treatment.

The problem underlying the patent was to provide a method for generating stable tetanus toxoid vaccine preparations.

This problem was not solved by all process variants included in claim 1. Firstly, depending on the degree of purity of the starting material, for some of the variants the problem did not arise. Secondly, due to the broad parameter ranges by which process conditions were characterised, it was inherently unlikely that all embodiments resulted in stable tetanus toxoid preparations. Therefore, in view of decision T 939/92, since the problem as formulated was not solved by substantially all embodiments, it could not be taken into account for the assessment of inventive step.

Moreover, the patent did not make it plausible that the problem was solved, because the only example did not fall under the claim. Following decision T 1329/04 this was a reason for denying inventive step.

It was known from document D14 that tetanus vaccines made from pre-purified toxin and toxoided with formaldehyde were unstable.

Lysine had successfully been used to prevent reversion of numerous other toxoids generated from purified toxins, for example diphtheria and pertussis, see documents D2, D6, D9, D10, D14 and D22. Therefore it was obvious to use this compound also for the stabilisation of tetanus toxoid preparations.

The remaining features of claim 1 were routinely used by the skilled person in formaldehyde-based detoxification methods, see documents D2 and D22.

Auxiliary request 2

Admission

In the written submissions the respondent had stated that it could not identify auxiliary requests other than the one then submitted. It would therefore come as a surprise and be consequently unfair to admit a new auxiliary request which is different from the one on file.

Inventive step

Pre-incubation with glutaraldehyde as a detoxifying agent for toxoiding tetanus toxin in combination with the later addition of lysine was disclosed in Table V of document D25. Therefore, the new feature in claim 1 belonged to the common general knowledge of the skilled person and would therefore be routinely applied by him/her. Consequently, the subject-matter of claim 1 of this request did not involve an inventive step either.

Sufficiency of disclosure

The example in the patent was not performed according to the conditions specified in the claim, because the Lf content of the starting material was not 250 Lf/ml as required by the claimed process but 200 Lf/ml. Therefore, the disclosure of the invention in the patent was insufficient.

XII. The respondent's arguments, as far as they are relevant for the present decision, may be summarised as follows:

Main request

Inventive step

The formaldehyde-based method disclosed in document D2 was the closest prior art.

The problem underlying the patent was the provision of an alternative or improved method for producing tetanus toxoid suitable for inclusion in a tetanus vaccine.

The burden was with the appellant to show that the claimed subject-matter was not a solution to the problem.

The problem of reversion of tetanus vaccines made from pre-purified toxin and toxoided with formaldehyde was neither derivable from document D14 nor from document D16. In particular, the statement in document D14 in paragraph A.3.3.4 on page 115 that care must be taken to avoid reversion was a standard safety warning of the World Health Organisation (WHO) and would not have been taken seriously by the skilled person without support from scientific evidence.

Due to structural differences between the different toxins, a skilled person would not have used lysine for stabilising tetanus toxoid, even though it had been used for this purpose for diphtheria or pertussis toxoids.

Even if the skilled person had identified lysine as a possible stabilising agent, he/she would not have used it, because there was no reasonable expectation of success in the context of tetanus toxin detoxification.

Auxiliary request 2

Admission

The request did not raise formal or new substantive issues. It should therefore be allowed into the proceedings.

Rule 57a EPC

The request was filed as an answer to the board's conclusion that the subject-matter of the main request lacked an inventive step.

Inventive step

It was taught on page 31 of document D25 that lysine inhibited the detoxification of tetanus toxin by glutaraldehyde. Therefore, the disclosure in document D25 rather gave the skilled person the suggestion to avoid lysine. Consequently, there was no reason for him/her to even consider pre-incubation with the detoxifying agent before addition of the allegedly stabilising agent.

Sufficiency of disclosure

An example was not required in order to fulfil the requirements of Article 83 EPC.

Reasons for the Decision

Admissibility of the appeal

1. The opposition was filed in the name of "Aventis Pasteur Limited". In view of a document submitted in a different case before it (see above section VI), the board became aware of the fact that this name was changed on 16 December 2004, the new name being "Sanofi Pasteur Limited". The opponent's notice of appeal was filed with a letter dated 13 January 2005 in the name of "Aventis Pasteur Limited", i.e. the former company name which, however, was no longer the correct name at the time of filing the appeal.

Hence, when the appeal was filed it did not comply with the provisions of Rule 64(a) EPC in combination with Rule 26(2)(c) EPC, because the name indicated in the notice of appeal was not the correct name of the appealing company.

1.1 Upon invitation by the present board at the oral proceedings, pursuant to Rule 65(2) EPC, the appellant has requested the correction of the name.

The correction of an appellant's name is allowable if it transpires from the facts that a mistake has been made and if the correction does not reflect a change of mind as to who the appellant should be (see for example decision T 97/98, OJ EPO 2002, 183).

1.2 Since it is obvious in the present case that the old name of the same legal person was erroneously used when the appeal was filed, the board accepts the requested correction of the name.

Admission into the proceedings of documents D11 to D26

2. Documents D11 to D14 were filed shortly before the oral proceedings held during opposition proceedings. The opposition division, in exercising its discretion in accordance with Article 114(2) EPC, decided not to admit these documents. With regard to document D14 the opposition division criticised that it was not a complete document. With the statement of grounds of appeal, the appellant filed documents D11 to D13 again, together with a complete copy of document D14.

3. Article 114(2) EPC allows the board to decide on the admission of documents filed during appeal proceedings. Therefore, the board does not deem it necessary to consider whether or not the opposition division has correctly exercised its discretion under Article 114(2) EPC not to admit documents D11 to D14 to the opposition proceedings.

4. The board considers documents D11 to D14 relevant for finding a decision since their disclosure allows the board to get a more complete picture of the field of toxoids used as vaccines before the priority date of the patent. Documents D15 to D24, filed with the statement of grounds of appeal, and documents D25 and D26, filed with the respondent's response to that statement, are considered relevant for the same reason. Moreover, all the documents were filed at the earliest point in time during the appeal proceedings. None of the parties objected to their admission. Hence the board has decided to admit documents D11 to D26 into the proceedings.

Main request

5. The present main request corresponds to the sole request before the opposition division. The only relevant issues with regard to it are that of inventive step and sufficiency of disclosure.

Inventive step

6. To assess inventive step, this board, in line with the normal practice of the boards of appeal of the European Patent Office, will apply the "problem and solution approach". This involves as a first step identifying the closest prior art.

The closest prior art

7. The closest prior art relates to subject-matter from which the claimed invention could most easily be made by the skilled person and thus provides the strongest basis for a challenge of obviousness. According to the case law this requirement is fulfilled by prior art disclosing subject-matter conceived for the same objective as the claimed invention (Case Law of the Boards of Appeal of the European Patent Office, 5th edition 2006, I.D.3.1).

8. The objective of the present invention is to generate tetanus toxoid preparations from pre-purified tetanus toxin that are stable during storage or, in other words, that do not revert to toxicity so that they can be used as vaccines without any danger of intoxication (see for example paragraphs [0001], [0004] and [0005] of the patent).

9. Document D2 was considered by both parties as the closest prior art document. This document is chapter 17 of a book published in 1990 and discloses inter alia processes for the preparation of tetanus and diphtheria vaccines. In part VI of it (starting on page 259) entitled "Detoxification of purified diphtheria and tetanus toxins" it is stated:

"Several methods have been described for the purification of diphtheria and tetanus toxins: [...]. The partially purified or highly purified toxin preparations can then be detoxified by the conventional formaldehyde treatment."

On page 260 it is then stated:

"Early studies carried out with purified diphtheria toxin showed that the toxoids prepared from highly purified toxin became toxic after dilution and removal of excess formaldehyde [8,49-51]. Later on it was shown that if lysine, 0,0025 M, was included in the detoxification solution, the toxoids obtained were stable and immunogenic [8,50,52]."

And finally it is stated on the same page:

"An alternative way to formaldehyde detoxification has been developed by Relyveld using glutaraldehyde. Diphtheria and tetanus toxins can be completely and irreversibly inactivated by treatment for a short time with 0.025 M or 0.0025 M glutaraldehyde, respectively. Lysine is still necessary for the irreversible detoxification of diphtheria, but not for tetanus, toxins."

9.1 Thus, document D2 discloses that tetanus vaccines can be prepared by detoxifying purified tetanus toxin with either formaldehyde or glutaraldehyde. As regards stability, it is explicitly stated that the glutaraldehyde-based process results in stable preparations. No explicit comment is given anywhere in document D2 about the stability or instability of tetanus vaccine preparations obtained from purified tetanus toxins after detoxification with formaldehyde. However, given the disclosure in document D2 of the instability of diphtheria vaccines made from purified diphtheria toxin with formaldehyde, the board considers the disclosure of document D2 to implicitly convey that there is a risk of instability of tetanus toxoids generated from purified tetanus toxins by formaldehyde detoxification.

9.2 Therefore, since the objective of the patent is the provision of a stable tetanus vaccine (see point 8 above), the board concludes that the glutaraldehyde-based detoxification process disclosed in document D2 is closest to the claimed invention.

10. The problem arising for the skilled person in view of the closest prior art is the provision of an alternative process for the preparation of stable tetanus toxoids from purified tetanus toxin.

11. According to the appellant there are two reasons why claim 1 must be regarded as involving subject-matter which does not solve this problem and the problem cannot therefore be taken as a basis for the assessment of inventive step.

11.1 The appellant submits that it is known, for example from document D2 (page 256; see also paragraph 12.1 below), that impurities present in the medium of the toxin preparation add to a stabilising effect during detoxification with formaldehyde. Therefore, the stability of tetanus toxoid preparations generated by the formaldehyde-based tetanus toxin detoxification method (as for example disclosed in document D2 on page 256) depended on the purity of the tetanus toxin used as a starting product. Given that the specific activity of the starting product according to claim 1 may be as low as 2000 Lf/mg PN (corresponding to a purity of about 70%, see paragraph [0009] of the patent), it necessarily follows that the claim encompasses process variants which would result in stable preparations even without the addition of lysine. The above formulated problem does not apply to those variants.

However, the board has no evidence at its disposal that tetanus toxoid preparations made from tetanus toxin purified to the lower purity levels encompassed by the claim would indeed be stable without the addition of lysine. For that reason alone, the board is not convinced by the appellant's argument.

11.2 Moreover, the appellant referred to decision T 939/92 (OJ EPO 1996, 309) where the board held that a problem can only be considered as solved and therefore be taken into account for assessing inventive step if it is solved by substantially all the subject-matter of a claim. The appellant submits that, in the present case, due to the definition of process parameters by broad ranges of values, it is inherently unlikely that all possible process variations falling under the terms of claim 1 result in stable tetanus toxoid preparations. For example, if tetanus toxin is incubated at pH 6.0 and a temperature of 45ºC for several weeks, then a large volume of precipitate is formed which would hamper further processing of the preparation (see appellant's submission of 14 March 2005).

11.3 The board considers that a claim to a process defining different process parameters by broad ranges of values can formally encompass process variants which may not achieve the desired result if the extreme values of ranges are combined, as in the appellant's example. However, in the board's view, the skilled person would be aware that such combinations of process conditions might not generate the desired result and would not apply them. Therefore, an argument to the effect that a claim directed to a process encompasses variants not solving the problem, where that argument relies solely on rather unrealistic combinations of process conditions, does not convince the board.

12. The appellant also referred to decision T 1329/04 of 28 June 2005 in which the board held in point 12 of the reasons that the definition of an invention as being a contribution to the art, i.e. as solving a technical problem and not merely putting one forward, required that it is at least made plausible by the disclosure in the application that its teaching indeed solves the problem it purports to solve. The appellant argues that the patent does not make it plausible that the problem is solved because one of the conditions of the only example disclosing a process generating stable detoxified tetanus toxin preparations lies outside claim 1, namely the toxin concentration of the starting product (paragraph [0029]). It is 200 Lf/ml according to the example, whereas it is 250 Lf/ml or more according to claim 1.

12.1 The detoxification of tetanus toxin relies on a reaction of the free amine group of a lysine residue in the toxin molecule with the aldehyde group of formaldehyde, leading to either intra- or intermolecular cross-linking or to a linkage with peptidic impurities in the reaction medium. The final result of this reaction is the formation of a methylene bridge. If a sufficient amount of these bridges have formed, the toxin is no longer toxic and the toxoiding is irreversible, i.e. the preparation is stable (document D2, page 256). Given this underlying chemistry of the detoxification process, the board considers that in fact the effectiveness of the reaction is not dependent on the concentration of tetanus toxin alone but on the relation of concentrations between tetanus toxin, aldehyde and lysine. The example disclosed in paragraph [0029] illustrates these relations. Therefore, in the board's view, although the initial toxin concentration of the example is not within the claimed range, the patent makes it plausible that the problem is solved.

Obviousness

13. The process according to claim 1 and the process identified as the closest prior art (see point 9.2 above) differ in the following features:

- The starting product, purified tetanus toxin, has a specific activity of 2000 Lf/mg PN or more and an Lf content of 250 Lf/ml or more; in document D2 the concentration of the starting product is not disclosed.

- The starting product is detoxified with formaldehyde in a concentration of 0.2 to 1% (V/V); according to the process of the closest prior art, detoxification is made with glutaraldehyde at a concentration of 0.0025 M.

- According to claim 1 detoxification takes place in the presence of lysine at a concentration of 0.005 to 0.25 M; lysine is absent in the glutaraldehyde-based detoxification of tetanus toxin according to document D2.

- The reaction takes place from 24 to 32 days, at a pH from 6.0 to 8.0 and at a temperature of 30 to 45ºC. As to the reaction conditions, it is only mentioned in document D2 that the inactivation treatment is carried out for "a short time".

14. For the assessment of whether or not the solution proposed in claim 1 was obvious, it has thus to be examined whether the skilled person starting from the closest prior art process - the detoxification of purified tetanus toxin by glutaraldehyde - was led in an obvious manner by the prior art on file to solve the problem of providing an alternative process for the preparation of stable tetanus toxoids from purified tetanus toxin by modifying the features of the closest prior art process such as to arrive at the combination of features according to the claimed process.

Thus, the first question to be considered is whether or not it was obvious to use formaldehyde instead of glutaraldehyde as a detoxification agent.

Formaldehyde as a detoxifying agent

15. The formaldehyde-based treatment as an effective method to detoxify tetanus and diphtheria toxins was discovered in the 1920s inter alia by Ramon (document D2, Introduction). The use of glutaraldehyde for the detoxification of toxins for the preparation of vaccines only started in the early 1970s (document D25, the paragraph bridging pages 24 and 25). However, at the priority date of the patent, the use of formaldehyde was still more widespread. It is stated in the introduction of document D2, published in 1990, i.e. approximately two years before the priority date of the patent:

"Diphtheria and tetanus vaccines are presently still prepared using the method described by Ramon."

This is confirmed by a statement in document D14, also published in 1990, on page 111:

"The most common method of preparing toxoids from toxins is by means of formaldehyde."

Thus, the board concludes that, at the priority date of the patent, formaldehyde was the means of first choice for toxoiding bacterial toxins for vaccine preparation.

16. It is an issue, however, whether or not the skilled person would have considered tetanus vaccine preparations made from purified tetanus toxins with formaldehyde to be stable upon storage. The respondent maintains that the skilled person would not be aware of an instability of such preparations and that, therefore, the addition of lysine as a stabilising agent could not be obvious. In particular, in the absence of any supporting scientific evidence on the real existence of such a danger for reversion, the skilled person would not have taken seriously the advice in document D14 on page 115 that "particular care must be taken to avoid a reversion to toxin" if detoxification starts from purified tetanus toxin, but would have regarded it as a standard warning passage which the WHO included in relation to all toxin-derived vaccines, as could be seen from the equivalent passage in relation to diphtheria toxin.

16.1 However, document D14 is a publication of the WHO describing "Requirements for diphtheria, tetanus pertussis and combined vaccines". It is not imaginable for the board that the skilled person would ignore an advice, even if it is made in the absence of scientific support, given by a renowned organisation such as the WHO in the context of such a serious issue as the preparation of vaccines made from toxins. This is especially so since tetanus toxin is the second most poisonous substance known (Affidavit of Prof. Montecucco dated 21 March 2005 = document D23, point 11). Moreover, as already noted above in point 9.1, the risk of instability in tetanus vaccine preparations made from purified tetanus toxins with formaldehyde transpires also from the disclosure of document D2.

Lysine as a stabilising agent

17. The next question arising with regard to the evaluation of the obviousness of the claimed process is whether or not the skilled person would have considered lysine as a means of stabilisation.

17.1 Documents D2, D6, D9, D10, D14 and D22 relate to the subject of the stability of diphtheria and pertussis vaccine preparations generated by formaldehyde treatment. Thus, none of the above-mentioned documents is explicitly concerned with the stabilisation of tetanus toxoids. Therefore, the respondent maintains that, given size and sequence differences between tetanus toxin and the other bacterial toxins, the skilled person would not have considered applying the teaching of any of these documents.

17.2 The board disagrees. The reaction mechanism underlying the process of detoxification with formaldehyde is explained on page 256 of document D2. It involves a cross-linkage between the Epsilon-amino groups of lysine residues in the toxin, resulting in a) internal cross-linking within one toxin molecule, b) cross-linking of different toxin molecules or c) cross-linking between toxin molecules and peptide molecules present in the medium. This basic reaction is common to all formaldehyde-based detoxification processes, which is also accepted by the respondent (page 8 of the submission dated 5 December 2005). Therefore, in the board's view, the skilled person aiming at providing an alternative process for the preparation of stable tetanus toxoids would not see size and sequence differences as a reason deterring him/her from considering prior art dealing with the detoxification of toxins other than tetanus toxin.

17.3 Document D2 discloses on page 260 that lysine has been successfully used to stabilise diphtheria toxoids prepared from purified toxin (see point 9.1 above). Also, document D10 on page 18 and document D14 on page 98 disclose that lysine is added during detoxification as a means of preventing reversion of diphtheria toxoids. In document D22 the effects of various amino acids during the detoxification of purified diphtheria toxin with formaldehyde on a number of properties of the toxoids produced, inter alia their stability, are compared. When discussing the results the authors come to the conclusion that "[o]f all the amino acids tested, lysine is the only one which gives a product having all the required desiderata of high antigenicity and stability, freedom from reversal and good adsorption on to aluminium phosphate." (page 187, paragraph 4 of the Discussion). In the worked examples of document D6 purified diphtheria toxin is toxoided in the presence of formaldehyde and: lysine (example 1), lysine and alanine (examples 2 and 3) and ethylene-diamine (examples 4 and 5). No explicit stability measurements are reported. It is mentioned however on page 3 that the lysine-treated toxoid of example 1 has been incorporated in a diphtheria vaccine. Finally, document D9 discloses a method for preparing stable pertussis toxoids by a treatment of the toxin with formaldehyde in the presence of lysine or glycine in combination with N-acetyltryptophane, where the combination with lysine had the best effect (column 4).

Thus, documents D2, D10 and D14 disclose lysine as the sole stabilising agent. Documents D6, D9 and D22 disclose lysine as a stabiliser among others or in combination with others, but lysine is either explicitly (D22) or implicitly (D6 and D9) favoured.

17.4 Hence, in view of these disclosures, the board concludes that, at the priority date of the patent, lysine was one of the known stabilising agents, if not the preferred agent, in formaldehyde-based detoxification processes of diphtheria and pertussis toxoids. Therefore, in the board's view, the skilled person would also have envisaged it for stabilising tetanus toxoid preparations made from purified tetanus toxin.

18. The respondent submitted that even if the skilled person had identified lysine as a possible candidate for stabilisation of such tetanus toxoids, it was not obvious to use it because there was a lack of reasonable expectation of success in the context of tetanus toxin detoxification.

18.1 However, in the board's view, consideration of the expectation of success is not appropriate in the present case for assessing obviousness. This approach has been developed in the field of genetic engineering to take account of the fact that in this field one may easily conceive of inventions to be made by genetic engineering, yet realising them may cause problems in view of difficulties known or experienced when starting the project. Thus, the evaluation of the "reasonable expectation of success" involves an analysis of the prior art with the aim of determining the degree of confidence conveyed by it to the skilled person that an envisaged result, which has never before been achieved, will be obtained.

According to the case law, a skilled person who, in view of the teaching in the prior art, has already clearly envisaged a group of compounds or a compound and then determines by routine tests whether such compound or compounds have the desired effect, is in a try and see situation (see e.g. decision T 1599/06 of 13 September 2007, point 20.2 of the reasons).

18.2 In the present case lysine had already been identified in the prior art to prevent diphtheria and pertussis vaccine preparations from reversion (see point 17.3 above). For the determination of whether it has this same activity in the context of the detoxification of tetanus toxin, it is enough to perform well-known tests. It is true that the outcome of such tests is not clearly predictable. However, this would not have deterred the skilled person from performing them in the light of the activity reported in the prior art (in this context see decision T 149/93 of 23 March 1995, point 5.2 of the reasons).

19. In summary, the board concludes that the skilled person would have chosen lysine as stabilising agent in an obvious way when aiming at detoxifying purified tetanus toxin.

Other features of claim 1

Specific activity of toxin

20. In document D2, in the part relating to detoxification of purified diphtheria and tetanus toxins it is stated (page 259): "Several methods have been described for the purification of diphtheria and tetanus toxins: [...]. With these methods, diphtheria and tetanus toxins can be easily obtained at a purity ranging from 85% to 95%. The partially purified or highly purified toxin preparations can then be detoxified by the conventional formaldehyde treatment."

According to paragraph [0009] of the patent a specific activity of 2000 Lf/mg is equivalent to a purity of about 70%. The starting material according to the process of claim 1 has a specific activity of 2000 Lf/mg or more.

Toxin concentration

21. Document D22 discloses detoxification of purified tetanus toxin with formaldehyde at a starting concentration of 500 Lf/ml (page 177, last paragraph). According to claim 1 of the patent an initial concentration of 250 Lf/ml or more of purified tetanus toxin is used.

Formaldehyde and lysine concentration, pH, temperature, duration

22. Document D2 teaches the detoxification of the purified toxin preparation by the conventional formaldehyde treatment (see quotation in point 20 above). A "conventional formaldehyde treatment" is disclosed in document D2 in part V entitled "Preparation of conventional diphtheria and tetanus vaccines". The detoxification reaction is carried out by adding formaldehyde to a final concentration of 0,5%, at a pH of 7.6, at 37ºC for four weeks. According to claim 1, purified tetanus toxin is incubated with formaldehyde at a concentration of 0.2 to 1%, at a pH of 6.0 to 8.0, at 30 to 45ºC, for 24 to 32 days.

Furthermore, document D2 discloses on page 260 a concentration of lysine of 0,025 M in a detoxification process of purified diphtheria toxin. According to claim 1, the concentration is between 0.005 and 0.25 M.

23. The board thus concludes that the further process conditions recited in claim 1, i.e. specific activity and concentration of toxin, formaldehyde and lysine concentration, pH, temperature and duration of the reaction, encompass conditions which would be ordinarily applied by the skilled person.

24. Hence, all features of claim 1 encompass obvious modifications for a skilled person in view of the problem to be solved. Therefore, the subject-matter of claim 1 of the patent as granted does not involve an inventive step.

Auxiliary request 2

Admission of the request

25. This request was filed at the oral proceedings after the board had announced its decision that the main request lacks an inventive step (see above section VII). Article 10b(3) of the Rules of Procedure of the Boards of Appeal (RPBA) stipulates that amendments sought to be made after oral proceedings have been arranged may not be admitted if they raise issues which the board or the other party or parties cannot reasonably by expected to deal with without adjournment. The subject-matter of present claim 1 corresponds to that of claim 5 of the main request. Therefore, it was at stake when considering the patentability of the main request. Moreover, the amendment does not raise formal issues (see below). Consequently, the board considered that the new request could be dealt with properly by the appellant and the board at the oral proceedings. Therefore, in accordance with Article 10b(1) RPBA, the board has decided to admit the request.

Rule 57a EPC

26. The amendment has been made in order to overcome the objection of lack of inventive step against claim 1 of the main request, i.e. of claim 1 as granted. Hence, the requirements of Rule 57a EPC are fulfilled.

Articles 84 and 123(2)(3) EPC

27. Since Article 84 EPC is not a ground of opposition, and since Article 100(c) EPC has not been invoked as a ground of opposition in the present case, the claims of the auxiliary request are to be examined for the requirements of Articles 123(2) and 84 EPC only with regard to amendments in relation to the granted claims. The evaluation of the requirements of Article 123(3) EPC is also made by comparison with the granted claims.

27.1 Claim 1 of the auxiliary request is a combination of claims 1 and 5 as granted. In other words, present claim 1 and claim 5 as granted relate to the same subject-matter. Claims 2 to 8 of the auxiliary request correspond to claims 2 to 4 and 6 to 9 as granted. Hence, none of the present claims is open to objections under Article 84 EPC.

27.2 The newly added feature in claim 1 "wherein the purified toxin is preincubated with the formaldehyde in the absence of the lysine for from 20 to 40 minutes at from 35 to 40ºC" is taken verbatim from claim 5 as originally filed (which is worded identically to claim 5 as granted; see section I above). The requirements of Article 123(2) EPC are therefore fulfilled.

27.3 Claim 1 results from a combination of two granted claims, i.e. claims 1 and 5, which combination results in the limitation of the scope with regard to claim 1 as granted. The requirements of Article 123(3) EPC are therefore fulfilled.

Inventive step

Closest prior art and problem

28. The board considers that the closest prior art with respect to claim 1 of this request and the underlying problem are the same as those defined with respect to claim 1 of the patent as granted (see points 9.2 and 10 above), i.e. the detoxification of purified tetanus toxin with glutaraldehyde disclosed in document D2 represents the closest prior art and the problem is to be formulated as the provision of an alternative process for the preparation of a stable tetanus toxoid from purified tetanus toxin.

29. The patent makes it plausible that the above-formulated problem is solved for the reasons given in respect of the main request in point 12 above and because the process described in the example of paragraph [0029] of the patent encompasses a pre-incubation step: "Aliquots were toxoided as follows: 1. 0,25% (v/v) formaldehyde in the form of formalin was added to one aliquot and the mixture was preincubated for 30 minutes at 37ºC. L-lysine monohydrochloride was subsequently added...".

Obviousness

30. It has already been found above in relation to claim 1 of the patent as granted that the skilled person would have carried out the toxoiding reaction with formaldehyde in the presence of lysine in order to obtain stable tetanus toxoid preparations and that he/she would also ordinarily have applied process conditions encompassed by the remaining features of claim 1.

31. As regards the new feature of pre-incubation of tetanus toxin with formaldehyde in the absence of lysine, the appellant submits that Table V of document D25 disclosed such a process step and that therefore it was an obvious alternative to the known simultaneous presence of lysine and formaldehyde in a process for preparing stable tetanus toxoids.

32. Table V of document D25 reads as follows:

FORMULA/TABLE/GRAPHIC

32.1 Thus, in point f of the legend to Table V a process where lysine is added only after the toxin was contacted with the detoxifying agent is indeed disclosed.

33. However, it has to be borne in mind that for the purpose of the interpretation of a document in the context of inventive step, in order to avoid hindsight considerations, the teaching being perceived by a skilled person in view of the problem that he/she wants to solve must be determined by taking into account the whole information content of that document.

33.1 An evaluation of document D25 from the perspective of the skilled person looking for a process for the preparation of stable tetanus toxoids reveals, in the board's view, the following:

Table V reports on the effect of lysine on the stability of tetanus toxoids in a detoxification process of tetanus toxin by glutaraldehyde. Inter alia, glutaraldehyde concentrations were varied, i.e. they were 0.00263 M, 0,00131 M, 0,00066 M and 0.00033 M (see column 1), as were the order of the additions and the number of compounds, i.e. procedure A consisted in the rapid subsequent addition of toxin, glutaraldehyde and lysine (see legend to the table, point b); procedure B consisted in the rapid subsequent addition of toxin, lysine and glutaraldehyde (see legend to the table point b); furthermore, lysine was added after contact of toxin with glutaraldehyde ("preincubation"; see legend to the table, point f); and no lysine was added (column 3 of the table "No").

In the last column of the table, data on the stability of the different preparations are given, as far as they have been determined.

The results are as follows: The stability of preparations made at a glutaraldehyde concentration of 0,00263 was not determined (see first four lines of Table V, last column). At a concentration of 0.00131 M glutaraldehyde, stable preparations were obtained when no lysine was added (see line 5 of Table V; last column) and after pre-incubation of the toxin with glutaraldehyde (see line 8 of Table V; last column). The only stable preparations at a concentration of 0,00066 M glutaraldehyde were obtained in the absence of lysine and at a contact time between toxin and detoxifying agent of 60 and 90 minutes, while of the two pre-incubated preparations tested for stability, both reverted to toxicity.

In summary, three of four processes which resulted in stable solutions were carried out in the absence of lysine. The fourth stable preparation was obtained under pre-incubation conditions. However, a stable solution was also obtained with the same amount of glutaraldehyde and with the same time of contact but without pre-incubation.

Therefore, in the board's view, altogether, the results of the table would rather indicate to a skilled person that lysine is not necessary for stabilisation and not that the point in time of the addition of lysine has an influence on stability.

Moreover, in the board's view, the remainder of the document does not contain any information which would change this view. The comment in the text on the results in Table V is as follows (page 31, first full paragraph): "The effect of lysine on detoxication of tetanus toxin by GA (note by the board: "GA" is used as an abbreviation for glutaraldehyde) has been

evaluated.**(26) This was done in view of results showing the stabilizing effect of lysine on diphtheria toxoid.**(14) As shown in Table V, addition of lysine inhibited detoxication of tetanus toxin by GA." (emphasis added by the board).

33.2 In view of the foregoing, the board thus concludes that, although document D25 discloses a process including pre-incubation of the detoxifying agent with the toxin before the addition of lysine in Table V, this step would not have been regarded as a suitable process step by the skilled person wanting to prepare stable tetanus toxoid preparations.

Hence, document D25 is not considered as rendering obvious the feature in claim 1 "wherein the purified toxin is pre-incubated with the formaldehyde in the absence of lysine for from 20 to 40 minutes at from 35 to 40ºC". Since document D25 was the only document cited in this respect by the respondent and since the board is not aware of any other document on file disclosing said feature, it is concluded that the subject-matter of claim 1 as well as the subject-matter of the dependent claims 2 to 8 involves an inventive step.

The requirements of Article 56 EPC are fulfilled.

Sufficiency of disclosure

34. The appellant's argument that the disclosure is insufficient since the relevant example does not describe a process falling under the claim because the initial toxin concentration is 200 Lf/ml and not 250 Lf/ml or more as required by claim 1 (see also point 12 above), does not convince the board. An example is not a necessary prerequisite for the acknowledgement of sufficiency of disclosure, if the invention can be carried out in view of information given in the patent or known to the skilled person from the prior art. In the board's view, present claim 1 itself describes the invention, i.e. a process for the preparation of tetanus toxoid, in such a precise manner that, in the absence of any further relevant evidence, the board considers the requirement of Article 83 EPC already as fulfilled on the basis of the disclosure in the claim alone.

Therefore, the requirements of Article 83 EPC are considered as fulfilled.

Entscheidungsformel

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the department of first instance with the order to maintain the patent in amended form on the basis of claims 1 to 8 of auxiliary request 2, filed at the oral proceedings, and a description still to be adapted.

Footer - Service & support
  • Unterstützung
    • Aktualisierungen der Website
    • Verfügbarkeit der Online-Dienste
    • FAQ
    • Veröffentlichungen
    • Verfahrensbezogene Mitteilungen
    • Kontakt
    • Aboverwaltung
    • Offizielle Feiertage
    • Glossar
Footer - More links
  • Jobs & Karriere
  • Pressezentrum
  • Single Access Portal
  • Beschaffung
  • Beschwerdekammern
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Impressum
  • Nutzungsbedingungen
  • Datenschutz
  • Barrierefreiheit